title: Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections.
abstract: Despite the complexity and heterogeneity of mood disorders, basic and clinical research studies have begun to elucidate the pathophysiology of depression and to identify rapid, efficacious antidepressant agents. Stress and depression are associated with neuronal atrophy, characterized by loss of synaptic connections in key cortical and limbic brain regions implicated in depression. This is thought to occur in part via decreased expression and function of growth factors, such as brain-derived neurotrophic factor (BDNF), in the prefrontal cortex (PFC) and hippocampus. These structural alterations are difficult to reverse with typical antidepressants. However, recent studies demonstrate that ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist that produces rapid antidepressant actions in treatment-resistant depressed patients, rapidly increases spine synapses in the PFC and reverses the deficits caused by chronic stress. This is thought to occur by disinhibition of glutamate transmission, resulting in a rapid but transient burst of glutamate, followed by an increase in BDNF release and activation of downstream signaling pathways that stimulate synapse formation. Recent work demonstrates that the rapid-acting antidepressant effects of scopolamine, a muscarinic receptor antagonist, are also associated with increased glutamate transmission and synapse formation. These findings have resulted in testing and identification of additional targets and agents that influence glutamate transmission and have rapid antidepressant actions in rodent models and in clinical trials. Together these studies have created tremendous excitement and hope for a new generation of rapid, efficacious antidepressants.
authors.affiliation: Laboratory of Molecular Psychiatry, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.
authors.forename: Ronald S
authors.initials: RS
authors.lastname: Duman
mesh_terms: D000818:Animals; D001921:Brain / Q000503:physiopathology*; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism; D003863:Depression / Q000188:drug therapy / Q000503:physiopathology*; D005973:Glutamine / Q000378:metabolism*; D006801:Humans; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism; D009435:Synaptic Transmission / Q000502:physiology*
chemical_list: D019208:Brain-Derived Neurotrophic Factor; D016194:Receptors, N-Methyl-D-Aspartate; D005973:Glutamine
keywords: BDNF; glutamate; ketamine; mTORC1; prefrontal cortex; rapamycin; scopolamine; stress; synaptogenesis
references.citation: Biol Psychiatry. 2008 Feb 15;63(4):349-52
references.pmid: 17643398
references.citation: J Neurosci. 2007 Oct 24;27(43):11496-500
references.pmid: 17959792
references.citation: Biol Psychiatry. 2012 Oct 1;72(7):555-61
references.pmid: 22521148
references.citation: Ann N Y Acad Sci. 2003 Nov;1003:273-91
references.pmid: 14684452
references.citation: Neuropsychopharmacology. 2010 Nov;35(12):2378-91
references.pmid: 20686454
references.citation: Nat Rev Drug Discov. 2008 May;7(5):426-37
references.pmid: 18425072
references.citation: JAMA Psychiatry. 2013 Jan;70(1):31-41
references.pmid: 22945416
references.citation: Neuropharmacology. 2004 Mar;46(4):457-67
references.pmid: 14975669
references.citation: Eur J Pharmacol. 2008 Sep 11;592(1-3):96-102
references.pmid: 18634781
references.citation: Curr Mol Pharmacol. 2009 Nov;2(3):215-36
references.pmid: 20021460
references.citation: Science. 2011 Sep 9;333(6048):1456-8
references.pmid: 21778362
references.citation: Neurosci Biobehav Rev. 2009 May;33(5):699-771
references.pmid: 19428491
references.citation: N Engl J Med. 2003 Apr 3;348(14):1333-41
references.pmid: 12672860
references.citation: J Neurosci. 1997 Oct 1;17(19):7503-22
references.pmid: 9295396
references.citation: Curr Drug Targets. 2007 May;8(5):583-602
references.pmid: 17504103
references.citation: Am J Psychiatry. 2003 Aug;160(8):1516-8
references.pmid: 12900317
references.citation: Arch Gen Psychiatry. 2010 Aug;67(8):793-802
references.pmid: 20679587
references.citation: Am J Psychiatry. 2006 Jan;163(1):153-5
references.pmid: 16390905
references.citation: Biol Psychiatry. 2013 Aug 15;74(4):257-64
references.pmid: 23206319
references.citation: Nature. 2008 Oct 16;455(7215):894-902
references.pmid: 18923511
references.citation: Neuroreport. 2006 Jun 26;17(9):863-7
references.pmid: 16738477
references.citation: Neuron. 2009 Feb 12;61(3):340-50
references.pmid: 19217372
references.citation: Psychosom Med. 2009 Feb;71(2):171-86
references.pmid: 19188531
references.citation: Dev Neurobiol. 2012 Jun;72(6):878-90
references.pmid: 21898852
references.citation: Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):751-6
references.pmid: 18178625
references.citation: Physiol Genomics. 2012 Oct 17;44(20):981-91
references.pmid: 22930738
references.citation: Mol Psychiatry. 2011 Nov;16(11):1068-70
references.pmid: 21502951
references.citation: Eur J Pharmacol. 2010 Aug 10;639(1-3):81-90
references.pmid: 20371229
references.citation: Arch Gen Psychiatry. 2005 Jun;62(6):617-27
references.pmid: 15939839
references.citation: J Neurosci. 2000 Jan 1;20(1):8-21
references.pmid: 10627576
references.citation: Pharmacol Biochem Behav. 2001 Oct-Nov;70(2-3):187-92
references.pmid: 11701187
references.citation: Int J Neuropsychopharmacol. 2012 May;15(4):429-34
references.pmid: 22114864
references.citation: Biol Psychiatry. 2006 Jun 15;59(12):1116-27
references.pmid: 16631126
references.citation: Neuropsychopharmacology. 2013 Oct;38(11):2268-77
references.pmid: 23680942
references.citation: Nat Rev Neurosci. 2009 Sep;10(9):647-58
references.pmid: 19693029
references.citation: Science. 2008 Apr 18;320(5874):385-8
references.pmid: 18420937
references.citation: J Neurosci. 1994 Dec;14(12):7680-7
references.pmid: 7996203
references.citation: Brain Res. 2009 Oct 13;1293:108-13
references.pmid: 19361488
references.citation: Brain Struct Funct. 2008 Sep;213(1-2):93-118
references.pmid: 18704495
references.citation: Cell. 2007 Oct 19;131(2):391-404
references.pmid: 17956738
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):201-17
references.pmid: 15694227
references.citation: Neuroscience. 1995 Nov;69(1):89-98
references.pmid: 8637636
references.citation: Mol Psychiatry. 2009 Jul;14(7):681-95
references.pmid: 19153574
references.citation: J Mol Psychiatry. 2013 Sep 17;1(1):15
references.pmid: 25408908
references.citation: Brain Behav Immun. 2013 Jul;31:105-14
references.pmid: 23261775
references.citation: Neuropsychopharmacology. 2013 Apr;38(5):729-42
references.pmid: 23303054
references.citation: Biol Psychiatry. 2012 Dec 1;72(11):e27-8
references.pmid: 22771240
references.citation: Mol Psychiatry. 2010 Jan;15(1):80-92
references.pmid: 19621014
references.citation: Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16481-6
references.pmid: 19805324
references.citation: J Neurosci. 2009 Jul 8;29(27):8688-97
references.pmid: 19587275
references.citation: Curr Opin Cell Biol. 2011 Dec;23(6):730-7
references.pmid: 21996102
references.citation: Nat Rev Neurosci. 2013 Sep;14(9):609-25
references.pmid: 23942470
references.citation: Science. 2010 Aug 20;329(5994):959-64
references.pmid: 20724638
references.citation: Neuropharmacology. 2011 Dec;61(8):1419-23
references.pmid: 21903115
references.citation: J Neurochem. 2004 Feb;88(3):635-46
references.pmid: 14720213
references.citation: Science. 2007 Dec 7;318(5856):1645-7
references.pmid: 18063801
references.citation: Curr Opin Neurobiol. 2009 Apr;19(2):146-53
references.pmid: 19523814
references.citation: Neuropsychopharmacology. 2009 Oct;34(11):2376-89
references.pmid: 19606083
references.citation: J Neurosci. 1997 Apr 15;17(8):2921-7
references.pmid: 9092613
references.citation: Science. 2006 Oct 6;314(5796):140-3
references.pmid: 17023662
references.citation: J Neurochem. 2010 Dec;115(6):1608-20
references.pmid: 20969570
references.citation: Biol Psychiatry. 2010 Mar 1;67(5):446-57
references.pmid: 20015486
references.citation: Biol Psychiatry. 2007 Sep 1;62(5):496-504
references.pmid: 17585885
references.citation: Biol Psychiatry. 2012 Jun 1;71(11):996-1005
references.pmid: 22036038
references.citation: J Clin Invest. 2009 Apr;119(4):717-25
references.pmid: 19339763
references.citation: Am J Psychiatry. 2006 Jan;163(1):28-40
references.pmid: 16390886
references.citation: Front Neuroanat. 2013 Jul 17;7:23
references.pmid: 23882190
references.citation: Biol Psychiatry. 2013 Aug 15;74(4):238-9
references.pmid: 23885752
references.citation: Nature. 2011 Jun 15;475(7354):91-5
references.pmid: 21677641
references.citation: Neuropharmacology. 2009 Sep;57(3):193-200
references.pmid: 19523965
references.citation: Neuropsychopharmacology. 2011 Nov;36(12):2375-94
references.pmid: 21814182
references.citation: Biol Psychiatry. 2000 Feb 15;47(4):351-4
references.pmid: 10686270
references.citation: Brain Res Bull. 1998 Apr;45(6):607-13
references.pmid: 9566505
references.citation: Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):359-64
references.pmid: 18172209
references.citation: Nat Rev Neurosci. 2009 Jun;10(6):423-33
references.pmid: 19469026
references.citation: Nat Med. 2012 Sep;18(9):1413-7
references.pmid: 22885997
references.citation: Br J Pharmacol. 2001 Oct;134(4):871-9
references.pmid: 11606328
references.citation: Biol Psychiatry. 2008 Oct 15;64(8):691-700
references.pmid: 18639865
references.citation: Neuropsychopharmacology. 2007 Feb;32(2):471-82
references.pmid: 17063153
references.citation: Novartis Found Symp. 2008;289:152-60; discussion 160-4, 193-5
references.pmid: 18497101
references.citation: Biol Psychiatry. 1999 May 1;45(9):1085-98
references.pmid: 10331101
references.citation: Biol Psychiatry. 2010 Mar 1;67(5):432-8
references.pmid: 20074703
references.citation: Mol Pharmacol. 2000 Oct;58(4):802-13
references.pmid: 10999951
references.citation: Neuropsychopharmacology. 2014 Jan;39(2):329-38
references.pmid: 23929545
references.citation: Mol Psychiatry. 2002;7(8):837-44
references.pmid: 12232776
references.citation: Physiol Rev. 2007 Jul;87(3):873-904
references.pmid: 17615391
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:28-33
references.pmid: 23643674
references.citation: Biol Psychiatry. 2013 Nov 15;74(10):742-9
references.pmid: 23751205
references.citation: J Neurosci. 2012 Mar 21;32(12):4092-101
references.pmid: 22442074
references.citation: Biol Psychiatry. 2012 Oct 1;72(7):537-47
references.pmid: 22705040
references.citation: Arch Gen Psychiatry. 2006 Oct;63(10):1121-9
references.pmid: 17015814
references.citation: Trends Neurosci. 2012 Jan;35(1):47-56
references.pmid: 22217452
references.citation: Neuropharmacology. 2003 Jun;44(8):1013-21
references.pmid: 12763094
references.citation: Neuropsychopharmacology. 2010 Nov;35(12):2479-88
references.pmid: 20736989
references.citation: Int J Neuropsychopharmacol. 2011 Sep;14(8):1127-31
references.pmid: 21557878
references.citation: Mol Psychiatry. 2014 Sep;19(9):978-85
references.pmid: 24126931
references.citation: Hippocampus. 2011 Mar;21(3):253-64
references.pmid: 20095008
references.citation: J Neurosci. 2011 Dec 14;31(50):18464-78
references.pmid: 22171048
references.citation: Biol Psychiatry. 2011 Apr 15;69(8):754-61
references.pmid: 21292242
references.citation: Science. 2011 Dec 23;334(6063):1731-4
references.pmid: 22194582
references.citation: Mol Psychiatry. 2009 Aug;14(8):764-73, 739
references.pmid: 18982002
references.citation: CNS Neurol Disord Drug Targets. 2007 Jun;6(3):219-33
references.pmid: 17511618
references.citation: Mol Psychiatry. 2011 Mar;16(3):252-64
references.pmid: 20661246
references.citation: J Neurochem. 2004 Sep;90(5):1258-68
references.pmid: 15312181